Implementing CDC guidance for infant neuroimaging and infant and placental Zika virus testing by Centers for Disease Control and Prevention (U.S.)
CDC’s Response to Zika
IMPLEMENTING CDC GUIDANCE FOR INFANT NEUROIMAGING 
AND INFANT AND PLACENTAL ZIKA VIRUS TESTING
Based on maternal Zika virus exposure and laboratory test results
Notes: (1) This tool summarizes general CDC guidance for the following scenarios. The tool only addresses live births. Please consult CDC* or your state or local health department for case-specific questions. Health departments should adapt CDC guidance depending on local capacity and circumstances.
 (2) In all cases, infants with anomalies consistent with congenital Zika syndrome should also be evaluated for other etiologies of congenital anomalies.
 (3) Infant serum and urine should be tested for Zika virus by Zika NAT, and infant serum for Zika virus IgM antibodies. If CSF is obtained, it can also be tested. Please refer to the published guidance for more information. 
 (4) Placental testing includes testing of formalin-fixed or formalin-fixed, paraffin-embedded placenta, umbilical cord, and fetal membranes by ZIKV RT-PCR. Microscopic evaluation of fixed tissues is conducted in selected cases. Please note that a positive RT-PCR result from placental testing cannot distinguish 
between maternal and fetal infection; therefore, a positive RT-PCR result from the placenta can confirm maternal Zika infection but cannot be used to confirm congenital Zika infection in the infant. Negative NAT results on placental tissue do not exclude maternal ZIKV since the duration of ZIKV persistence in the 
placenta is unknown and the samples evaluated may not reflect the placenta in its entirety. Please refer to the website for further guidance.    
Timing of Zika virus exposure† relative to 
timing of maternal specimen collection
EXPOSURE† WITHIN ANY TIME PERIOD ALL EXPOSURE† WITHIN 12 WEEKS OF SPECIMEN COLLECTION (I.E., EXPOSURE† IS COMPLETELY WITHIN TESTING WINDOW§)
Test results and interpretation from 
maternal specimens (e.g.serum, urine, 
and whole blood ) >>
Recent ZIKV infection
NAT positive  
OR 
non-negative Zika IgM¶ AND 
Zika PRNT**  ≥ 10, and dengue PRNT** < 10 
Recent flavivirus infection,  
specific virus cannot be identified**
non-negative Zika IgM¶ AND                            
Zika PRNT** ≥ 10, and dengue PRNT** ≥ 10   
No evidence of ZIKV infection
Zika IgM negative 
OR 
non-negative Zika IgM¶ AND Zika PRNT** < 10  
Presumptive recent** ZIKV or flavivirus infection 
non-negative Zika IgM¶ AND PRNT** pending
Not tested
Additional maternal testing on serum, 
urine, and whole blood >>
Additional maternal testing not indicated
Additional Maternal Testing: Follow up PRNT 
results, if indicated according to lab guidance. If 
maternal IgM is inconclusive, repeat IgM testing in 
accordance with EUA.
Maternal Testing: Recommended; specimens 




with congenital Zika 
syndrome††
Neuroimaging: Head ultrasound recommended; 
should be performed before hospital discharge.  
If technically difficult, consider MRI or CT.
Neuroimaging: Head ultrasound recommended; 
should be performed before hospital discharge.  
If technically difficult, consider MRI or CT.
Neuroimaging: Head ultrasound recommended; 
should be performed before hospital discharge.  
If technically difficult, consider MRI or CT.
Neuroimaging: Head ultrasound recommended; 
should be performed before hospital discharge.  
If technically difficult, consider MRI or CT.
Neuroimaging: Head ultrasound recommended; 
should be performed before hospital discharge.  
If technically difficult, consider MRI or CT.
Infant Testing: Recommended; specimens should 
be collected within 2 days of birth. Consider testing 
CSF if serum and urine results are negative. 
Infant Testing: Recommended; specimens should 
be collected within 2 days of birth. Consider testing 
CSF if serum and urine results are negative.
Infant Testing: Recommended; specimens should 
be collected within 2 days of birth. Consider testing 
CSF if serum and urine results are negative.
Infant Testing: Recommended; specimens should 
be collected within 2 days of birth. Do not wait for 
maternal test results. Consider testing CSF if serum 
and urine results are negative.
Infant Testing: Recommended; specimens should 
be collected within 2 days of birth. Consider testing 
CSF if serum and urine results are negative.
Placental Testing: Not indicated; no added 
diagnostic value given known maternal ZIKV 
diagnosis.§§
Placental Testing: Should be considered to aid in 
maternal diagnosis.
Placental Testing: Fix and store placenta until 
infant results are available. Depending on infant test 
results, placental testing can be considered to aid in 
maternal diagnosis.¶¶
Placental Testing: Fix and store placenta until 
maternal PRNT results are available. Based on 
maternal PRNT result interpretation, refer to 
appropriate column. 
Placental Testing: Fix and store placenta until 
maternal results are available. Based on maternal 
test result interpretation, refer to appropriate 
column.
Phenotypically normal
Neuroimaging: Head ultrasound recommended; 
should be performed before hospital discharge. 
Neuroimaging: Head ultrasound recommended; 
should be performed before hospital discharge. 
Neuroimaging: Not indicated.
Neuroimaging: Head ultrasound recommended; 
should be performed before hospital discharge. 
Can be deferred until next outpatient visit if infant 
appears well and no concerns for loss to follow up.
Neuroimaging: Head ultrasound recommended; 
should be performed before hospital discharge. 
Can be deferred until next outpatient visit if infant 
appears well and no concerns for loss to follow up. 
Infant Testing: Recommended; specimens should 
be collected within 2 days of birth.
Infant Testing: Recommended; specimens should 
be collected within 2 days of birth.
Infant Testing: Not indicated.
Infant Testing: Specimens should be collected 
within 2 days of birth and stored. Decision to test 
the infant can be deferred until maternal test results 
are available. Based on maternal PRNT result 
interpretation, refer to appropriate column. 
Infant Testing: Specimens should be collected 
within 2 days of birth and stored. Decision to test 
the infant can be deferred until maternal test results 
are available.
Placental Testing: Not indicated; no added 
diagnostic value given known maternal ZIKV 
diagnosis.§§
Placental Testing: Should be considered to aid 
maternal diagnosis.
Placental Testing: Not indicated.
Placental Testing: Fix and store placenta until 
maternal PRNT results are available. Based on 
maternal PRNT result interpretation, refer to 
appropriate column.
Placental Testing: Fix and store placenta until 
maternal results are available. Based on maternal 
test result interpretation, refer to appropriate 
column.
Abbreviations: CT= Computed Tomography; EUA = Emergency Use Authorization; IgM = Immunoglobulin M; MRI= 
Magnetic Resonance Imaging; NAT = Nucleic Acid Test (includes rRT-PCR); PRNT = Plaque Reduction Neutralization 
Test; rRT-PCR = Real-time Reverse Transcription-Polymerase Chain Reaction; RT-PCR = Reverse Transcription-
Polymerase Chain Reaction; ZIKV = Zika virus.
* Please contact CDC Zika Pregnancy Hotline at 770-488-7100 or zikamch@cdc.gov.
† Possible Zika virus exposure is defined as travel to or residence in an area with risk of Zika or sex without a condom 
with someone who traveled to or lived in an area with risk of Zika.
§ Start and end date of exposure are both are within the 12-week testing window.
¶ Non-negative serology terminology varies by assay and examples include positive, equivocal, presumptive positive, 
or possible positive results. For explanation of a specific interpretation and informaton on each assay, refer to 
https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika, under the “Labeling” bullet 
for the specific assay. Inconclusive maternal IgM specimens should be retested in accordance with EUA. If the 
inconclusive maternal IgM cannot be reconciled, refer to the relevant exposure category “Not tested” column, and 
base decision to test placenta on maternal and/or infant test results.
**  Currently, PRNT confirmation is not routinely recommended for individuals living in Puerto Rico. In Puerto Rico, for 
“presumptive recent ZIKV” guidance, refer to the column for “recent ZIKV infection;” and for “presumptive recent 
flavivirus infection” guidance, refer to the column for “Recent flavivirus, specific virus cannot be identified.”
† † Including but not limited to: microcephaly; structural brain anomalies (e.g., decreased brain volume, calcifications); 
posterior eye anomalies (e.g., chorioretinal scarring, optic nerve hypoplasia); contracture of one or more joints; and 
functional neurologic abnormalities (e.g., spasticity/hypertonia, dystonia/dyskinesia). For complete list of anomalies 
please check the CDC Zika virus pregnancy outcomes website.
§§  In exceptional circumstances, placental testing may be considered in consultation with CDC at 770-488-7100 or 
zikamch@cdc.gov.
¶¶ If infant testing is done it should be performed before placental testing, if possible. If (1) infant NAT (rRT-PCR) is 
positive for Zika, or (2) infant IgM is Zika positive or equivocal AND infant or maternal PRNT is positive for Zika but 
negative for dengue, then there is limited utility of placental testing. If other infant test results are obtained, placental 
testing may provide another opportunity to identify maternal infection that would otherwise go unrecognized.
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Timing of Zika virus exposure† relative to 
timing of maternal specimen collection
ALL OR PART OF THE EXPOSURE† OCCURRED MORE THAN 12 WEEKS PRIOR TO SPECIMEN COLLECTION  
(I.E., EXPOSURE† IS COMPLETELY OR PARTIALLY OUTSIDE TESTING WINDOW***)
Test results and interpretation from 
maternal specimens (e.g.serum, urine, 
and whole blood ) >>
No evidence of recent ZIKV infection
 NAT negative AND Zika IgM negative†††
Presumptive recent ZIKV or flavivirus infection 
non-negative Zika IgM¶ AND PRNT** pending
Not tested
Additional maternal testing on serum, 
urine, and whole blood >>
Additional Maternal Testing: Not indicated.
Additional Maternal Testing: Follow up PRNT results, if indicated according to lab 
guidance. If maternal IgM is inconclusive, repeat IgM testing in accordance with EUA.




with congenital Zika 
syndrome††
Neuroimaging: Head ultrasound recommended; should be performed before hospital 
discharge. If technically difficult, consider MRI or CT.
Neuroimaging: Head ultasound recommended; should be performed before hospital 
discharge. If technically difficult, consider MRI or CT.
Neuroimaging: Head ultasound recommended; should be performed before hospital 
discharge. If technically difficult, consider MRI or CT.
Infant Testing: Recommended; specimens should be collected within 2 days of birth. 
Consider testing CSF if serum and urine results are negative.
Infant Testing: Recommended; specimens should be collected within 2 days of birth. 
Consider testing CSF if serum and urine results are negative.
Infant Testing: Recommended; specimens should be collected within 2 days of birth. 
Consider testing CSF if serum and urine results are negative.
Placental Testing: Fix and store placenta until infant results are available. Depending on 
infant test results, placental testing can be considered to aid maternal diagnosis.¶¶
Placental Testing: Can be considered to aid maternal diagnosis. Can consider fixing and 
storing placenta until maternal PRNT results are available. Based on maternal PRNT result 
interpretation, refer to appropriate column.
Placental Testing: Fix and store placenta until infant results are available. Depending 
on infant test results, placental testing can be considered to aid maternal diagnosis.¶¶
Phenotypically normal
Neuroimaging: Head ultrasound recommended; should be performed before  
hospital discharge. 
Neuroimaging: Head ultrasound recommended, should be performed before hospital 
discharge. Can be deferred until next outpatient visit if infant appears well and no 
concerns for loss to follow up. 
Neuroimaging: Head ultrasound recommended; should be performed before hospital 
discharge. Can be deferred until next outpatient visit if infant appears well and no 
concerns for loss to follow up. 
Infant Testing: Should be considered§§§; specimens should be collected within 2 days  
of birth. 
Infant Testing: Specimens should be collected within 2 days of birth and stored. Decision 
to test the infant can be deferred until maternal test results are available. Based on 
maternal PRNT result interpretation, refer to appropriate column. 
Infant Testing: Should be considered§§§; specimens should be collected within 2 
days of birth. 
Placental Testing: If infant testing is performed, fix and store placenta until infant results 
are available. Depending on infant test results, placental testing can be considered to aid 
maternal diagnosis.¶¶ Consult CDC if infant testing is not performed.*
Placental Testing: Can be considered to aid maternal diagnosis. Can consider fixing and 
storing placenta until maternal PRNT results are available. Based on maternal PRNT result 
interpretation, refer to appropriate column.
Placental Testing: If infant testing is performed, fix and store placenta until 
infant results are available. Depending on infant test results, placental testing can 
be considered to aid maternal diagnosis.¶¶ Consult CDC if infant testing is not 
performed.*
Abbreviations: CT= Computed Tomography; EUA = Emergency Use Authorization; IgM = Immunoglobulin M; MRI= 
Magnetic Resonance Imaging; NAT = Nucleic Acid Test (includes rRT-PCR); PRNT = Plaque Reduction Neutralization 
Test; rRT-PCR = Real-time Reverse Transcription-Polymerase Chain Reaction; RT-PCR = Reverse Transcription-
Polymerase Chain Reaction; ZIKV = Zika virus.
* Please contact CDC Zika Pregnancy Hotline at 770-488-7100 or zikamch@cdc.gov.
† Possible Zika virus exposure is defined as travel to or residence in an area with risk of Zika or sex without a condom 
with someone who traveled to or lived in an area with risk of Zika.
*** If maternal testing is performed >12 weeks after exposure and/or symptom onset, a negative Zika IgM or NAT result 
does not rule out recent maternal ZIKV infection because IgM antibody and viral ribonucleic acid levels decline over 
time.
† † † If PRNT testing also performed and is negative, please refer to ‘No evidence of ZIKV infection’ column in the ‘All 
exposure within 12 weeks of specimen collection’ section of this table.
¶  Non-negative serology terminology varies by assay and  examples include positive, equivocal, presumptive positive, 
or possible positive results. For explanation of a specific interpretation and informaton on each assay, refer to 
https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika, under the “Labeling” bullet 
for the specific assay. Inconclusive maternal IgM specimens should be retested in accordance with EUA. If the 
inconclusive maternal IgM cannot be reconciled, refer to the relevant exposure category “Not tested” column, and 
base decision to test placenta on maternal and/or infant test results.
** Currently, PRNT confirmation is not routinely recommended for individuals living in Puerto Rico. In Puerto Rico, for 
“presumptive recent ZIKV” guidance, refer to the column for “recent ZIKV infection;”  and for “presumptive recent 
flavivirus infection” guidance, refer to the column for  “Recent flavivirus, specific virus cannot be identified.”
† †  Including but not limited to: microcephaly; structural brain anomalies (e.g., decreased brain volume, calcifications); 
posterior eye anomalies (e.g., chorioretinal scarring, optic nerve hypoplasia); contracture of one or more joints; and 
functional neurologic abnormalities (e.g., spasticity/hypertonia, dystonia/dyskinesia). For complete list of anomalies 
please check the CDC Zika virus pregnancy outcomes website.
¶¶ If infant testing is done it should be performed before placental testing, if possible. If (1) infant NAT (rRT-PCR) is 
positive for Zika, or (2) infant IgM is Zika positive or equivocal AND infant or maternal PRNT is positive for Zika but 
negative for dengue, then there is limited utility of placental testing. If other infant test results are obtained, placental 
testing may provide another opportunity to identify maternal infection that would otherwise go unrecognized.
§§§  Infant testing should be considered because recent maternal ZIKV infection is not ruled out by negative maternal 
NAT or IgM, or when maternal testing has not been performed.  Specimens should be collected soon after birth, as 
Zika RNA and IgM antibodies decline over time.  
Notes: (1) This tool summarizes general CDC guidance for the following scenarios. The tool only addresses live births. Please consult CDC* or your state or local health department for case-specific questions. Health departments should adapt CDC guidance depending on local capacity and circumstances.
 (2) In all cases, infants with anomalies consistent with congenital Zika syndrome should also be evaluated for other etiologies of congenital anomalies.
 (3) Infant serum and urine should be tested for Zika virus by Zika NAT, and infant serum for Zika virus IgM antibodies. If CSF is obtained, it can also be tested. Please refer to the published guidance for more information. 
 (4) Placental testing includes testing of formalin-fixed or formalin-fixed, paraffin-embedded placenta, umbilical cord, and fetal membranes by ZIKV RT-PCR. Microscopic evaluation of fixed tissues is conducted in selected cases. Please note that a positive RT-PCR result from placental testing cannot distinguish 
between maternal and fetal infection; therefore, a positive RT-PCR result from the placenta can confirm maternal Zika infection but cannot be used to confirm congenital Zika infection in the infant. Negative NAT results on placental tissue do not exclude maternal ZIKV since the duration of ZIKV persistence in the 
placenta is unknown and the samples evaluated may not reflect the placenta in its entirety. Please refer to the website for further guidance.    
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